Stocks · News reference
8-K filing — AXON ENTERPRISE, INC. (AXON)
Filed: 2026-11-05 AccNo: 0001628280-26-071150 Size: 21 MB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
These Analysts Cut Their Forecasts On Axon Enterprise After Downbeat Q3 Results
Axon missed Q3 revenue and earnings estimates, cut FY26 guidance, and shares fell 14%; analysts lowered price targets.
Analysts Adjust Price Targets for Axon Enterprise Following Q3 Earnings
Multiple financial institutions, including Barclays, TD Cowen, and Piper Sandler, updated their price targets for Axon Enterprise, Inc. on November 6, 2026, following the company's third-quarter earnings report.
Axon Reports Q3 2026 Financial Results
Axon Enterprise, Inc. reported Q3 2026 revenue of $909 million, a 28% year-over-year increase, and a swing to net income of $57 million.
Axon Enterprise vs. Monday.com: Which Industrials Stock Is a Better Buy for 2027?
Axon Enterprise and Monday.com represent different investment approaches: Axon commands a premium valuation (P/E 55.7x) with strong 33.5% revenue growth and expanding cloud services in law enforcement, while Monday.com trades at a discount (P/E 17.2x) with slower 26.7% growth but superior cash generation. The article concludes Axon is the better choice for 2027 due to stronger momentum, despite Monday.com's attractive valuation and AI platform expansion.
Axon Enterprise vs. DocuSign: Which Industrials Stock Is a Better Buy in 2026?
Axon Enterprise and DocuSign represent different investment profiles: Axon offers faster growth (33.5% revenue growth) in public safety technology with a premium valuation (49.8x forward P/E), while DocuSign provides steadier cash generation (8.2% revenue growth) at a more reasonable valuation (16.6x forward P/E). Despite Axon's impressive growth prospects, the article recommends DocuSign for 2026 due to its more attractive valuation and reasonable forward multiples.